{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:12:58Z","timestamp":1793776378457,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023368","name":"Eisai Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tjpad.2025.100160","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:30:35Z","timestamp":1743982235000},"page":"100160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1047-9225","authenticated-orcid":false,"given":"Christopher","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadao","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-4021","authenticated-orcid":false,"given":"Amitabh","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-2511","authenticated-orcid":false,"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Dhadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kanekiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-6672","authenticated-orcid":false,"given":"Steve","family":"Hersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-8129","authenticated-orcid":false,"given":"Takeshi","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100160_bib0001","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tjpad.2025.100160_bib0002","article-title":"Alzheimer's disease","volume":"1","author":"Masters","year":"2015","journal-title":"Nature Rev"},{"key":"10.1016\/j.tjpad.2025.100160_bib0003","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2025.100160_bib0004","doi-asserted-by":"crossref","first-page":"b158","DOI":"10.1136\/bmj.b158","article-title":"Alzheimer's disease","volume":"338","author":"Burns","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.tjpad.2025.100160_bib0005","series-title":"World Alzheimer Report 2022","year":"2021"},{"key":"10.1016\/j.tjpad.2025.100160_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/ADR-220059","article-title":"Current and Future Trends in Biomarkers for the Early Detection of Alzheimer's Disease in Asia: expert Opinion","volume":"6","author":"Kandiah","year":"2022","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.tjpad.2025.100160_bib0007","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J Biomed Sci"},{"issue":"8","key":"10.1016\/j.tjpad.2025.100160_bib0008","first-page":"S167","article-title":"Current and evolving treatment strategies for the Alzheimer disease continuum","volume":"26","author":"Marasco","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.tjpad.2025.100160_bib0009","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: an Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.tjpad.2025.100160_bib0010","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 Pathway in Alzheimer's Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100160_bib0011","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer's disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nat Aging (Albany NY)"},{"key":"10.1016\/j.tjpad.2025.100160_bib0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100160_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100160_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100160_bib0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100160_bib0016","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100160_bib0017","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100160_bib0018","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100160_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032014","article-title":"Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation","volume":"7","author":"Sehlin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2025.100160_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000316530","article-title":"Heavy-chain complementarity-determining regions determine conformation selectivity of anti-A\u03b2 antibodies","volume":"8","author":"Sehlin","year":"2011","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.tjpad.2025.100160_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JAD-130029","article-title":"Specific Uptake of an Amyloid-\u03b2-Protofibril-Binding Antibody-Tracer in A\u03b2PP Transgenic Mouse Brain","volume":"37","author":"Magnusson","year":"2013","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.tjpad.2025.100160_bib0022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tjpad.2025.100160_bib0023","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.tjpad.2025.100160_bib0024","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1523\/JNEUROSCI.3537-10.2010","article-title":"Amyloid \u03b2-protein dimers rapidly form stable synaptotoxic protofibrils","volume":"30","author":"O'Nuallain","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.tjpad.2025.100160_bib0025","article-title":"Polymorphic structures of Alzheimer's \u03b2-amyloid globulomers","volume":"6","author":"Yu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2025.100160_bib0026","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/msj.20160","article-title":"Amyloid-\u03b2 oligomers: possible roles as key neurotoxins in Alzheimer's disease","volume":"77","author":"Lublin","year":"2010","journal-title":"Mt Sinai J Med"},{"issue":"3","key":"10.1016\/j.tjpad.2025.100160_bib0027","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100160_bib0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100160_bib0029","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100160_bib0030","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope: the Alzheimer's Disease Cooperative Study","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2025.100160_bib0031","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.tjpad.2025.100160_bib0032","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2025.100160_bib0033","unstructured":"EQ-5D-5l Available at: https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed November 19, 2024."},{"key":"10.1016\/j.tjpad.2025.100160_bib0034","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.dadm.2016.11.004","article-title":"Assessing quality of life in Alzheimer's disease: implications for clinical trials","volume":"6","author":"Kahle-Wrobleski","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.tjpad.2025.100160_bib0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/geront\/41.5.652","article-title":"The Zarit Burden Interview: a new short version and screening version","volume":"41","author":"B\u00e9dard","year":"2001","journal-title":"Gerontologist"},{"key":"10.1016\/j.tjpad.2025.100160_bib0036","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab Clarity AD: quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100160_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117037","article-title":"Proportion of intracerebral haemorrhage due to cerebral amyloid angiopathy in the East and West: comparison between single hospital centres in Japan and the United Kingdom","volume":"416","author":"Yakushiji","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.tjpad.2025.100160_bib0038","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0303-8467(91)90004-9","article-title":"Cerebral amyloid angiopathy in Chinese: incidence and significance","volume":"93","author":"Ng","year":"1991","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.tjpad.2025.100160_bib0039","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/01.STR.19.2.205","article-title":"Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama","volume":"19","author":"Masuda","year":"1988","journal-title":"Japan. Stroke."},{"key":"10.1016\/j.tjpad.2025.100160_bib0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5853\/jos.2023.04287","article-title":"Prevalence of Cerebral Amyloid Angiopathy Pathology and Strictly Lobar Microbleeds in East-Asian Versus Western Populations: a Systematic Review and Meta-Analysis","volume":"26","author":"De Kort","year":"2024","journal-title":"J Stroke"},{"key":"10.1016\/j.tjpad.2025.100160_bib0041","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100160_bib0042","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","article-title":"Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium","volume":"278","author":"Farrer","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100160_bib0043","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.14283\/jpad.2024.106","article-title":"Japanese subgroup analyses from EMERGE and ENGAGE, Phase 3 clinical trials of aducanumab in patients with early Alzheimer's disease","volume":"11","author":"Toda","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100160_bib0044","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese Patients with Early Alzheimer's Disease: subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.tjpad.2025.100160_bib0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:01:47Z","timestamp":1786482107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2274580725001050"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100160","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100160"}}